Matteo Gastaldi

Matteo Gastaldi

Auto-generated profile, based on publicly available information

Matteo Gastaldi

Department of Brain and Behavioral Sciences, University of Pavia, Italy

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Neurotherapeutics
Verified
Journal Article
Open access
MGMatteo Gastaldi
Matteo Gastaldi
ATAnaïs Thouin
Anaïs Thouin
AVAngela Vincent
Angela Vincent
Over the last 15 years it has become clear that rare but highly recognizable diseases of the central nervous system (CNS), including newly identified forms of limbic encephalitis and other encephalopathies, are likely to be mediated by antibodies (Abs) to CNS proteins. The Abs are directed against membrane receptors and ion channel-associated proteins that are expressed on the surface of neurons in the CNS, such as N-methyl D-aspartate receptors and leucine-rich, glioma inactivated 1 protein and contactin-associated protein like 2, that are associated with voltage-gated potassium channels. The diseases are not invariably cancer-related and are therefore different from the classical paraneoplastic neurological diseases that are associated with, but not caused by, Abs to intracellular proteins. Most importantly, the new antibody-associated diseases almost invariably respond to immunotherapies with considerable and sometimes complete recovery, and there is convincing evidence of their pathogenicity in the relatively limited studies performed so far. Treatments include first-line steroids, intravenous immunoglobulins, and plasma exchange, and second-line rituximab and cyclophosphamide, followed in many cases by steroid-sparing agents in the long-term. This review focuses mainly on N-methyl D-aspartate receptor- and voltage-gated potassium channel complex-related Abs in adults, the clinical phenotypes, and treatment responses. Pediatric cases are referred to but not reviewed in detail. As there have been very few prospective studies, the conclusions regarding immunotherapies are based on retrospective studies.

4 July 2020 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
MGMatteo Gastaldi
Matteo Gastaldi
SSSilvia Scaranzin
Silvia Scaranzin
SJSven Jarius
Sven Jarius
BWBrigitte Wildeman
Brigitte Wildeman
EZElisabetta Zardini
Elisabetta Zardini
DFDiego Franciotta
Diego Franciotta

2 December 2022 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
MGMatteo Gastaldi
Matteo Gastaldi
TFThomas Foiadelli
Thomas Foiadelli
GGGiacomo Greco
Giacomo Greco
SSSilvia Scaranzin
Silvia Scaranzin
EREleonora Rigoni
Eleonora Rigoni
DFDiego Franciotta
Diego Franciotta
Background IgG antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) define a subset of associated disorders (myelin oligodendrocyte glycoprotein associated disorders (MOGAD)) that can have a relapsing course. However, information on relapse predictors is scarce. The utility of retesting MOG-IgG over time and measuring their titres is uncertain. We aimed to evaluate the clinical relevance of longitudinal MOG-IgG titre measurement to predict relapses in patients with MOGAD. Methods In this retrospective multicentre Italian cohort study, we recruited patients with MOGAD and available longitudinal samples (at least one >3 months after disease onset) and tested them with a live cell-based assay with endpoint titration (1:160 cut-off). Samples were classified as ‘attack’ (within 30 days since a disease attack (n=59, 17%)) and ‘remission’ (≥31 days after attack (n=295, 83%)). Results We included 102 patients with MOGAD (57% adult and 43% paediatric) with a total of 354 samples (83% from remission and 17% from attack). Median titres were higher during attacks (1:1280 vs 1:640, p=0.001). Median onset titres did not correlate with attack-related disability, age or relapses. Remission titres were higher in relapsing patients (p=0.02). When considering the first remission sample available for each patient, titres >1:2560 were predictors of relapsing course in survival (log rank, p<0.001) and multivariate analysis (p<0.001, HR: 10.9, 95% CI 3.4 to 35.2). MOG-IgG seroconversion to negative was associated with a 95% relapse incidence rate reduction (incidence rate ratio: 0.05, p<0.001). Conclusions Persistent MOG-IgG positivity and high remission titres are associated with an increased relapse risk. Longitudinal MOG-IgG titres could be useful to stratify patients to be treated with long term immunosuppression.

11 November 2019 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
DFDiana Ferraro
Diana Ferraro
ATAlice Trovati
Alice Trovati
RBRoberta Bedin
Roberta Bedin
PNPatrizia Natali
Patrizia Natali
DFDiego Franciotta
Diego Franciotta
PSPatrizia Sola
Patrizia Sola

21 October 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
DFDiana Ferraro
Diana Ferraro
RBRoberta Bedin
Roberta Bedin
PNPatrizia Natali
Patrizia Natali
DFDiego Franciotta
Diego Franciotta
KSKrzysztof Smolik
Krzysztof Smolik
PSPatrizia Sola
Patrizia Sola
Background: Cerebrospinal fluid (CSF) kappa free light chains (KFLC) are gaining increasing interest as markers of intrathecal immunoglobulin synthesis. The main aim of this study was to assess the diagnostic accuracy (AUC) of the kappa index (CSF/serum KFLC divided by the CSF/serum albumin ratio) compared to CSF oligoclonal IgG bands (OCB) in predicting Multiple Sclerosis (MS) or a central nervous system infectious/inflammatory disorder (CNSID). Methods: We enrolled patients who underwent a diagnostic spinal tap throughout two years. KFLC levels were determined using a Freelite assay (Binding Site) and the turbidimetric Optilite analyzer. Results: Of 540 included patients, 223 had a CNSID, and 84 had MS. The kappa index was more sensitive (0.89 versus 0.85) and less specific (0.84 versus 0.89), with the same AUC (0.87) as OCB for MS diagnosis (optimal cut-off: 6.2). Adding patients with a single CSF IgG band to the OCB-positive group slightly increased the AUC (0.88). Likewise, the kappa index (cut-off: 3.9) was more sensitive (0.67 versus 0.50) and less specific (0.81 versus 0.97), with the same AUC (0.74) as OCB, for a CNSID diagnosis. Conclusion: The kappa index and CSF OCB have comparable diagnostic accuracies for a MS or CNSID diagnosis and supply the clinician with useful, complementary information.

8 December 2019 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
MGM. Gastaldi
M. Gastaldi
SMS. Mariotto
S. Mariotto
MGMaria Pia Giannoccaro
Maria Pia Giannoccaro
RIR. Iorio
R. Iorio
MZM. Zoccarato
M. Zoccarato
DFD. Franciotta
D. Franciotta